Open Access

DAL-1 attenuates epithelial-to mesenchymal transition in lung cancer

  • Xianliang Chen1,
  • Xiaoying Guan1,
  • Huiyu Zhang1,
  • Xiaobin Xie1,
  • Hongyan Wang1,
  • Jie Long1,
  • Tonghui Cai1,
  • Shuhua Li1,
  • Zhen Liu1 and
  • Yajie Zhang1Email author
Contributed equally
Journal of Experimental & Clinical Cancer Research201534:3

https://doi.org/10.1186/s13046-014-0117-2

Received: 12 October 2014

Accepted: 22 December 2014

Published: 22 January 2015

Abstract

Background

Epithelial-to mesenchymal transition (EMT) involves in metastasis, causing loss of epithelial polarity. Metastasis is the major cause of carcinoma-induced death, but mechanisms are poorly understood. Here we identify differentially expressed in adenocarcinoma of the lung-1 (DAL-1), a protein belongs to the membrane-associated cytoskeleton protein 4.1 family, as an efficient suppressor of EMT in lung cancer.

Methods

The relationship between DAL-1 and EMT markers were analyzed by using immunohistochemistry in the clinical lung cancer tissues. Quantitative real-time PCR and western blot were used to characterize the expression of the EMT indicator mRNAs and proteins in DAL-1 overexpressed or knockdown cells. DAL-1 combined proteins were assessed by co-immunoprecipitation.

Results

DAL-1 levels were strongly reduced even lost in lymph node metastasis and advanced pathological stage of human lung carcinomas. Overexpression of DAL-1 altered the expression of numerous EMT markers, such as E-cadherin, β-catenin Vimentin and N-cadherin expression, meanwhile changed the morphological shape of lung cancer cells, and whereas silencing DAL-1 had an opposite effect. DAL-1 directly combined with E-cadherin promoter and regulated its expression that could be the reason for impairing EMT and decreasing cell migration and invasion. Strikingly, HSPA5 was found as DAL-1 direct binding protein.

Conclusions

These results suggest that tumor suppressor DAL-1 could also attenuate EMT and be important for tumor metastasis in the early transformation process in lung cancer.

Keywords

Differentially expressed in adenocarcinoma of the lung-1 Epithelial-mesenchymal transition Lung cancer E-cadherin HSPA5

Background

Lung cancer is the leading cause of cancer-related mortality worldwide [1]. The main cause of death is the invasion and metastasis of tumor. EMT is the early event of lung cancer metastasis which is characterized by a loss of cell-cell adhesion and polarity, down-regulation of epithelial markers, and acquisition of mesenchymal markers and phenotype [2]. Thus, a better understanding of cellular and molecular mechanisms leading to metastatic dissemination of carcinoma cells is of utmost importance.

The human tumor suppressor gene DAL-1 was identified using Differential Display PCR as a gene whose expression was lacking in non-small cell lung cancer when compared with matched normal tissue [3]. Frequent loss of DAL-1 in cervical cancer [4], laryngeal squamous cell carcinoma [5], breast cancer [6] and esophageal squamous cell carcinoma [7] suggested that DAL-1 could be a tumor suppressor [8,9]. It has also been reported that loss of DAL-1 expression and methylation of the DAL-1 promoter are involved in development and progression of NSCLC (Non small cell carcinoma), providing a possible indicator of poor prognosis. Further studies demonstrated DAL-1 contained FERM (protein 4.1-ezrin-radixin-moesin) and SABD (spectrin-actin-binding domain) domain [10], enable it links to the transmembrane protein and cytoskeleton. Consequently, DAL-1 was considered as membrane associated protein contributing to cell shape, cell-cell and cell-matrix adhesion, and cell motility. DAL-1 also participates in the organization of cytoskeleton [6,11]. E-cadherin the key role in EMT and DAL-1 co-locate in the junction part of cells, therefore, loss of DAL-1 may associate with disruption of cell-cell adhesion, loss of polarity and cancer metastasis.

Herein, the effect of DAL-1 on EMT was identified, and its role on regulating EMT was illuminated in lung cancer cell lines. In this paper, we showed that expression of DAL-1 was downregulated in metastatic tumours and further identified DAL-1 as an EMT/metastasis suppressor.

Material and methods

Tissue samples and cell lines

The paraffin-embedded tissues of 190 primary lung cancers and 163 matched corresponding tumor adjacent tissues were obtained from patients who underwent primary surgical treatment without systemic chemotherapy or radiotherapy during the period 2005–2008. This project had the informed consents from all the patients and was approved by the First Affiliated Hospital of Guangzhou Medical University and informed consent was taken from all subjects. The average age of the patients at diagnosis was 60.34 years, ranging from 25 to 82 years. These cases included 77 squamous cell carcinomas (36 cases were well or moderately differentiated, 41 cases were poor differentiated), 85 adenocarcinomas (59 cases were well or moderately differentiated, 26 cases were poor differentiated), 11 adeno-squamous carcinomas (moderately differentiated), 6 small cell carcinomas (poor differentiated), 5 large-cell carcinomas (poor differentiated), 6 sarcomatoid carcinomas (poor differentiated). All samples were diagnosed and classified according to the World Health Organization grading system and the General Rules for Clinical.

The cell lines used in this study were purchased from American Type Culture Collection (ATCC).

Plasmids and stable cell lines

Plasmid pcDNA3-DAL-1 containing full-length DAL-1 coding region was kindly provided by Dr. Philip Washbourne (University of Oregon, USA). This plasmid was verified by DNA sequencing. The control vector pcDNA3 was purchased from Invitrogen (Grand Island, NY, USA). Lipofectamine® LTX & Plus Reagent (Invitrogen, Carlsbad, CA, USA) was used to transfect. Transfected condition was pre-optimized using pEGFP-C1 (Clontec, Mountain View, CA, USA) to monitor the transfection efficiency under inverted fluorescent microscopy.

To obtain stable transfectants, cells seeded in six-well plates were transfected with 2.5 μg/well plasmids using 10 μl/well Lipofectamine®LTX Reagent and 2.5 μl/well Plus Reagent. After 6 h incubation in serum and antibiotic free condition, the medium was replaced with RPMI 1640 containing 10% FBS, and the cells were cultured for 48 h before submitting to a 2-week selection in medium containing G418 (600 μg/ml).

Immunohistochemical staining

5-μm sections of paraffin-embedded tissues were treated with pepsin or 30 min and blocked with BSA for 30 min at room temperature. Tissue sections were then incubated with antibodies to DAL-1, E-cadherin, Snail or vimentin overnight at 4°C. Isotype control antibody (Sigma-Aldrich) was used as a negative control. Each slide was washed three times in TBS and incubated with biotinylated anti–mouse IgG (Vector Laboratories) in a humid chamber for 30 min. The positive cells were detected using peroxidase-conjugated streptavidin (Vector Laboratories) followed by 3′3-diaminobenzidine tetrahydrochloride (DAB; Vector Laboratories). The slides were counterstained with hematoxylin.

Dual-luciferase reporter assay

The E-cadherin promoter (643 bp, from-450 to +193) was cloned into pGL3-Enhancer vector (Promega). A549 cells were plated in 24-well plates at a density of 1 × 105 cells/well and grown overnight prior to transfection. The cells were transfected with either DAL-1 plasmid or control plasmid, and were co-transfected with pGL3-E-cadherin promoter plasmid and pGL3-TK plasmid. Forty-eight hours after transfection, the luciferase activities were analyzed by the Dual-luciferase system according to the manufacturer’s instruction (Promega). Three independent experiments were performed.

Chromatin immunoprecipitation analysis

ChIP analysis was carried out as described previously [12]. Briefly, Protein-DNA complexes were immunoprecipatited with DAL-1 antibody, with human IgG as a control, respectively. ChIP DNA was isolated with the Qiaquick PCR Purification Kit (Qiagen). Subsequent qPCR using 1⁄50 fraction of ChIP-enriched DNA and 100 nM primers in a total volume of 20 μl was conducted to assess the amount of DNA that had been precipitated. Standard curves from 0.1-100 ng of sonicated genomic DNA were also amplified by qPCR as a reference. DNA from these samples was then subjected to PCR analysis. Primers sets for E-cadherin promoter were 5′-gca gac tgg aag ggc gg-3′ and 5′-ggc agg cag ccc agc-3′.

Co-immunoprecipitation and mass spectrometric assay and protein identification

Co-immunoprecipitation was performed using Pierce® Co-IP kit (Thermo scientific, USA) following the manufacturer’s instruction. A549 cell lines stable tranfected either DAL-1 or control were lysed in ice-cold IP Lysis/Wash Buffer. After centrifugation at 13,000 g at 4°C for 10 min, the supernatant was collected. Pre-clear lysate using the control agarose resin before co-immunoprecipitation by the resin coupled with goat anti-DAL-1 polyclonal antibody. The immunoprecipitate was isolated by the elution buffer and separated by 10% SDS-PAGE. Sliver staining was used to detect the protein on the gel. The protein bands were submitted for tryptic peptide mass fingerprinting for identification by matrix-assisted laser desorption/ionization time-of-flight/time of flight mass spectrometry (MALDI-TOF/TOF-MS). Protein identification was performed by searching protein databases of Mascot (http://www.matrixscience.com).

Cells were lysed on ice for 30 min with a lysis buffer (150 Mm NaCl, 25 mM Hepes, pH 7.4, 10 mM NaF, 5 mM MgCl2 1 mM EGTA, 1% Nonidet P-40, protease inhibitors mixture:10 μg/ml aprotinin, 10 μg/ml leupeptin, 1 mM PMSF). Total lysates were precleared with protein G-Sepharose for 1 h at 4°C and then immunoprecipitated overnight with 2 μg of anti-Myc antibody (Santa Cruz Biotechnology). Protein G-Sepharose was then added, and the mixture was incubated for an additional 1 h at 4°C. The beads were washed three times with lysis buffer, followed by elution in Laemmli buffer. The proteins were subjected to SDS-PAGE and Western blotting according to standard procedures.

Migration and invasion assay

Cells were transfected with DAL-1, DAL-1 RNAi or negative control using Transfection Agent (Ambion, TX, USA) following manufacture’s protocol in 24-well plates. 24 h after transfection, Transwell migration assay and Matrigel invasion assay were performed separately using 24-well Transwell inserts with 8 μm pore size (Corning Costar Corp). For Transwell migration assay, 2 × 104 A549 or H460 cells suspended in 100 μl corresponding culture medium without fetal bovine serum (FBS) were loaded into the top chamber of transwell insert with non-coated membrane. For Matrigel invasion assay, 5 × 104 A549 or H460 cells were plated in 100 μl serum-free medium in the upper Matrigel-coated chamber instead. In both assays, the bottom chamber was containing 600 μl medium with 20% FBS. Cells were then allowed to migrated or invaded for 12 h at 37°C. The cells that migrated or invaded into the bottom chamber were fixed, stained with 1% nuclear fast red staining solution, visualized under phase contrast microscope and photographed. Total number of migrated or invaded cells was counted by IPP (Image-Pro Plus 6.0) software. All experiments were independently repeated at least three times.

Statistical analysis

Data were expressed as the mean ± SD for each group. The difference between groups was analyzed using a factorial model one-way analysis of variance. SPSS statistical software, version19.0 (Chicago, Illinois, USA) was used to carry out all analyses and P less than 0.05 was considered statistically significant. Each experiment was performed in triplicate.

Results

DAL-1 is down-regulated in lung cancer tissues

Several kinds of lung cancer cell lines, including A549, SPC-A1, PGC-L3, GLC-82, H1299, L78, and NCI-H460 were analyzed the DAL-1 mRNA and protein expression levels. GLC-82 and NCI-H460 cell lines were positive for DAL-1 mRNA and protein expression as indicated by RT-PCR products at the expected size of 153 bp and the specific protein binding band at the predicted size of 108 kDa. The endogenous DAL-1 expression had not been found in other kinds of cell lines (Additional file 1). To investigate the clinical importance of DAL-1 expression in lung cancer tissues and to explore its role on EMT, the expression of E-cadherin, Vimentin and Snail were examined on 190 cases of lung cancer tissues and 163 adjacent tissues samples by immunohistochemistry analysis (Figure 1). Lower expression of DAL-1 was found in tumor tissues compared with the normal adjacent tissues; higher expression of DAL-1 was found in well differentiated lung cancer tissues compared with poorly differentiated lung cancer tissues. Data present from Table 1 showed that expression of E-cadherin was lower (P < 0.05), whereas Vimentin and Snail protein expression levels (P < 0.05) were higher in poorly differentiated lung cancer tissues. Meanwhile, positive staining of DAL-1 protein was preferentially observed in tumors without lymph node metastasis (81/98, 82.6%) relative to those with lymph node metastasis (52/92, 56.5%, P < 0.05). Positive DAL-1 staining was significantly higher in tumors with pathological stages I (69/83, 83.1%) than in those with stage II, III and IV (77 of 107, 72.0%, P < 0.05).
Figure 1

Immunohistochemical staining on paraffin-embedded lung cancer tissue array sections. Tissue sections of lung cancer were analyzed by IHC staining. The positive staining was shown in brown color. The sections were counterstained with hemotoxylin to show nuclei. Representative images of DAL-1 staining is shown that lower expression of DAL-1 (A) and E-cadherin (B) could been seen in well- differentiated adenocarcinoma, while positive expressions of snail (C) and Vimentin (D) were mainly localized in cytoplasm or nucleus of the serous lung cancer cells. Magnification, ×200.

Table 1

Correlation of DAL-1, E-cadherin, vimentin, snail and clinical pathological characteristics

Clinical pathological characteristics

n

DAL-1

E-cadherin

Vimentin

Snail

+++

++

+

-

P

+++

++

+

-

P

+++

++

+

-

P

+++

++

+

-

P

Diameter (cm)

                     

>3

109

16

33

23

37

0.426

13

16

13

67

0.464

9

19

18

63

0.030

50

29

16

14

0.009

≤3

81

10

32

19

20

7

10

16

48

2

6

11

62

21

24

12

24

Differentiation

                     

Well/mild differentiated

106

18

50

19

19

0.000

16

17

21

52

0.003

0

5

15

86

0.000

36

27

17

26

0.263

Poor differentiated

84

8

15

23

38

4

9

8

63

11

20

14

39

35

26

11

12

Lymph metastasis

                     

N0

98

22

43

16

17

0.000

12

17

24

45

0.000

0

10

6

82

0.000

24

30

15

29

0.000

N1

92

4

22

26

40

8

9

5

70

11

15

23

43

47

23

13

9

Pathological stage

                     

I

83

18

39

12

14

0.000

9

14

22

38

0.015

0

8

5

70

0.000

17

25

13

28

0.000

II

57

3

17

18

19

6

6

5

40

4

5

12

36

21

16

13

7

III

42

5

8

9

20

5

5

1

31

5

11

11

15

28

9

2

3

IV

8

0

1

3

4

0

1

1

6

2

1

1

4

5

3

0

0

Spearman rank correlation analysis was applied to analyze the expression levels of DAL-1, E-cadherin, Snail, vimentin in lung cancer tissues (Table 2). The expression of DAL-1 was positively correlated with E-cadherin (r =0.710, P < 0.01), while negatively correlated with Vimentin (r = −0.499, P < 0.01) and Snail (r = −0.318, P < 0.01).
Table 2

Correlation of DAL-1, E-cadherin, vimentin, snail and clinical histology types

Group

n

DAL-1

E-cadherin

Vimentin

Snail

+++

++

+

-

P

+++

++

+

-

P

+++

++

+

-

P

+++

++

+

-

P

Tissue distribution

                     

Lung cancer

190

26

65

42

57

0.000

20

26

29

115

0.000

11

25

29

125

0.000

71

53

28

38

0.000

Para-carcinoma tissue

163

86

59

4

14

81

54

8

20

0

0

0

163

28

25

14

96

Histology types

                     

Squamous cell carcinoma

77

11

30

17

19

0.168

9

12

10

46

0.534

3

9

12

53

0.422

3

9

12

53

0.301

Small cell carcinoma

6

0

0

1

5

0

1

0

5

0

1

0

5

0

1

0

5

Adenocarcinoma

85

14

35

16

20

11

12

16

46

2

8

13

62

2

8

13

62

Large cell carcinoma

5

1

0

1

3

0

1

0

4

2

1

0

2

2

1

0

2

Adenosquamous carcinoma

11

0

0

5

6

0

0

2

9

3

2

4

2

3

2

4

2

Carcinoma sareomatodes

6

0

0

2

4

0

0

1

5

1

4

0

1

3

1

1

1

Based on our findings, the expression of DAL-1 is downregulated in lung cancer compared to normal tissues and significantly associated with disease progression, we suggest that decreased expression of DAL-1 may occur in the early stages of tumor development as well as be essential in maintaining tumorigenesis.

DAL-1 overexpression alters the expression of EMT markers

To verify whether DAL-1 is a crucial mediator of lung cancer, we established A549 cell line stably overexpressing DAL-1. We then analyzed DAL-1/A549 cells and the control cells through cell morphological observation. In the initial characterization of these cells, we observed a distinct morphological change in the cells overexpressing DAL-1. The A549 cells expressing DAL-1 underwent a phenotypic change and appear planar epithelial morphological shape, while the control A549 cells (Vector/A549) appear fibroblast-like mesenchymal cell morphological shape (Figure 2A).
Figure 2

Effect of DAL-1 overexpression on morphology and EMT markers in A549 cells. Cells were stably transfected with pcDNA3-DAL-1 or pcDNA3 plasmid respectively. A, Morphological changes in DAL-1 overexpression cells, from spindle-like mesenchymal morphology into epithelial morphology, by manifesting an increased cell-to-cell adhesion; B, Q-PCR analysis of the levels of EMT related markers after DAL-1stably transfected with pcDNA3-DAL-1 plasmid; The levels of E-cadherin and β-catenin mRNAs were higher in the cells treated with the pcDNA3-DAL-1 plasmid than in the pcDNA3 treated cells (mock) or A549 cells (blank), but the level of Vimentin and N-cadherin mRNAs were lower. The data are presented as the mean ± SD. n = 3, *P <0.05,#P <0.01. C, Western blot analysis of DAL-1 and EMT marker protein expression levels in A549 cells. When the cells were transfected with the pcDNA3-DAL-1, the protein levels of E-cadherin and β-catenin increased while protein levels of Vimentin N-cadherin were down-regulated.

Real-time quantitative PCR was used to assess the mRNA levels of EMT markers. The details of primer sequences for target genes were showed in Additional file 2: Table S1. As shown in Figure 2B,E-cadherin and β-catenin mRNAs were increased while Vimentin and N-cadherin mRNAs were decreased in DAL-1 stable transfected cells (*P <0.05, #P <0.01). Western blots also confirmed that DAL-1 overexpression resulted in an increment in E-cadherin and β-catenin expression and a reduction in Vimentin and N-cadherin expression at the protein level (Figure 2C).

We utilized the E-cadherin antibody and confocal microscopy to image E-cadherin expression in control and in DAL-1-overexpressed A549 cells. Figure 3A demonstrated that control A549 cells express relatively low levels of E-cadherin, whereas DAL-1-overexpressed cells expressed a great deal of E-cadherin localized in the plasma membrane.
Figure 3

DAL-1 attenuated cell migration and invasion in A549 cells. A, mock and DAL-1 overexpressed A549 cells were stained as described under “Experimental Procedures” and examined using confocal immunofluorescence microscopy, as follows: DAPI (blue, top panel) and E-cadherin (green). Merged images are in the bottom of each panel. B, a-b, Cell migration assay was performed after reintroduction of DAL-1 in A549 cells. c-d, Matrigel cell invasion assay was performed after re-expression of DAL-1 in A549 cells. e, The data are presented as mean ± SD for triplicate determinations, *P <0.05.

In our previous studies, we found that DAL-1 affected cell proliferation in lung cancer cells. Herein, the role of DAL-1 in cell migration and invasion was evaluated by the Matrigel-based transwell invasion assay. The images showed that DAL-1 overexpression inhibited cell migration (Figure 3B, a-b) and invasion (Figure 3B, c-d) of A549 cells. The result of statistical analysis was showed in Figure 3B, e (*P <0.05).

DAL-1 deficiency alters the expression of EMT markers

In the present study, we have observed an apparent endogenous expression of DAL-1 in NCI-H460 cells. To address the role of DAL-1 in NCI-H460 non-small cell lung cancer cell line, control and DAL-1 deficient cells were developed using non-silencing shRNA as a control and shRNA targeting DAL-1. As expected, DAL-1 knockdown resulted in reduction of E-cadherin mRNA expression level whereas Vimentin and N-cadherin mRNA levels were increased (Figure 4A). Similar results were obtained at the protein levels utilizing western blotting (Figure 4B). The Matrigel-based transwell invasion assay showed that DAL-1 knockdown promoted cell migration (Figure 4C, a-b) and invasion (Figure 4C, c-d) of A549 cells. Collectively, these data suggest that DAL-1 could inhibit EMT in lung cancer cell lines. The result of statistical analysis was showed in Figure 4C, e (*P <0.05).
Figure 4

DAL-1 deficiency alters the expression of EMT markers and metastasis ability. A, RNA extracts of control and DAL-1 knockdown NCI-H460 cells were subjected to RT-PCR to determine the expression of target genes as indicated. B, The expression of EMT markers E-cadherin, Vimentin and N-cadherin were measured in control and DAL-1 knockdown NCI-H460 cells by western blotting. C, Cell migration assay (a-b) and invasion assay (c-d) were performed after knockdown of DAL-1 in NCI-H460 cells. e, The data are presented as mean ± SD for triplicate determinations, *P <0.05.

DAL-1 transcriptionally regulates E-cadherin

Although it had been confirmed that expression of DAL-1 had positive correlation with E-cadheirn, we asked whether DAL-1 could regulate the activity of the E-cadherin promoter using a dual-luciferase reporter assay. Empty pcDNA3 vector or pcDNA3-DAL-1 plasmids were transfected into A549 cells together with an E-cadherin promoter. We examined the effect of DAL-1 overexpression or depletion on E-cadherin promoter luciferase reporter activity in the region of upstream 450 bp to downstream 193 bp. Figure 5A demonstrated that E-cadherin promoter activity was increased in DAL-1 overexpressed A549 cells comparing to the control cells (*P <0.05). These finding suggest that DAL-1 may impact on EMT through directly transcriptionally regulating E-cadherin.
Figure 5

DAL-1 transcriptionally regulates E-cadherin. A, Dual-luciferase reporter assay showed that DAL-1 regulated E-caderin at the transcriptional level. The data are presented as the mean ± SD. n = 6, *P <0.05. B, Schematic representation of the E-cadherin regulational area. Two regions were chosen to design the primers for qPCR. C, The result DNA from chromatin immunoprecipitation assay was analyzed by qPCR. D, Different primers were compounded and analyzed by PCR.

To directly confirm the binding of E-cadherin promoter to the endogenous DAL-1 protein in vivo, we performed ChIP assays in NCI-H460 cells by using anti-DAL-1 antibody. Figure 5B showed the schematic representation of the E-cadherin regulational area. Two regions were chosen to design the primers for qPCR. The result of qPCR analysis demonstrated that E-cadherin promoter (region 2) bound DAL-1 in vivo (Figure 5C). Different primers were compounded and analyzed by PCR. The PCR products were found using primers set spanning E-cadherin but none with IgG control primers (Figure 5D). The results showed that DAL-1 bound to the region 2 of E-cadherin promoter in vivo.

HSPA5 as a direct associated protein to DAL-1

Previous investigation highlighted that DAL-1 located in the lateral membrane of various epithelial cells, suggesting it could participate in adherent junction. We performed co-immunoprecipitation and mass spectrometric assay to examine the binding proteins to DAL-1. Figure 6A showed that the protein complex was co-immunoprecipitated with the DAL-1 antibody-coupled resin and followed SDS-PAGE for separation. Sliver staining image showed that six differentially bands appeared in the DAL-1 expression group while no specific band was observed at the same position of the control group. The gel of the bands was sent to MALDI TOF/TOF Mass Spectrometry for further analysis. Protein identification was finished by searching the PMF (Peptide Mass Fingerprint). Mascot search results demonstrated the details of masss pectrometric data (Additional files 3, 4, 5, 6, 7 and 8). The results from Additional file 2: Table S2 showed five differentially proteins including E-cadherin, HSPA5, P4HA1, Tubulin beta chain and 14-3-3ε.
Figure 6

HSPA5 is the direct binding protein to DAL-1 which contributes positively to EMT in lung cancer. A, Co-immunoprecipitation and mass spectrometric assay were performed to show the binding proteins to DAL-1. a, 4.1B; b, E-cadherin; c, HSPA5; d, P4HA1; e, Tubulin beta chain; f, 14-3-3ε. B, Endogenous co-immunoprecipitation analysis conformed that HSPA5 was the direct binding protein to DAL-1. C, The function of three designed HSPA5 RNA interference was determined by western blotting in A549 and NCI-H460 cells. D, The expression of EMT markers E-cadherin, N-cadherin and snail were measured in control and HSPA5 knockdown A549 or NCI-H460 cells by western blotting.

Further we investigated the association proteins by using co-immunoprecipitation experiment, whether they interacted with each other in lung cancer cells were tested. As shown in Figure 6B, HSPA5 was co-immunoprecipitated with DAL-1, whereas HSPA5 was not detected when applied with control IgG. The results indicated that DAL-1 associated with HSPA5 directly. Previous investigations have shown that HSPA5 may be an oncogene existing in cells. Moreover, we verified that HSPA5 konckdown could interfere with EMT by using RNA interference (RNAi) (Figure 6C). HSPA5 knockdown resulted in reduction of snail and N-cadherin expression levels whereas E-cadherin proein level was increased (Figure 6D). Evidence of HSPA5 promoted the EMT process together with previous results, it would be important to note that DAL-1 might inhibit HSPA5 then impact on EMT in lung cancer. However, we have not yet identified the partner of DAL-1 involved in this process and the mechanism linked to HSPA5 remains to be investigated.

Discussion

Tumor metastasis of is a complex multi-step and multi-stage process [13,14]. The mortality of lung cancer is often related to extensive metastasis [15,16]. During the metastasis cascade, carcinoma cells often activate EMT to underlie metastasis by promoting acquisition of migratory and invasive abilities [17-19]. Therefore, understanding the mechanisms inducing EMT is particularly important for developing strategies for clinical therapy [20-22]. DAL-1 was originally considered as a tumor growth suppressor gene based on its downregulation in lung adenocarcinoma [23,24]. Recent research reported that DAL-1 could suppress tumor metastasis [25].

As DAL-1 is associated with the cytoskeleton molecules and can regulate the cellular functions in adhesion and migration under physiological conditions [26,27], we speculated that DAL-1 might suppress metastasis via inhibiting EMT. Forced DAL-1 expression, however, abolished the metastatic capacity of a fibroblastoid, highly metastatic human lung cancer cell line through reversal to an epithelial phenotype. Loss of DAL-1 also predicted metastasis and impaired survival in a lung cancer tissue arrays from 190 patients, suggesting DAL-1 as an excellent biomarker for human metastatic lung cancer. Since DAL-1 abolishes metastatic capacity by re-inducing epithelial properties in dedifferentiated tumour cells, it might also be a candidate for gene therapy in metastatic cancer. DAL-1 overexpression altered the EMT markers expression, the expression of E-cadherin and β-catenin were upregulated, and expression of vimentin and N-cadherin were downregulated. Furthermore, inhibition of DAL-1 dramatically promoted the migration and invasion abilities of lung cancer cells. Our data together suggest that DAL-1 might contribute to the development of EMT.

Studies to unravel possible mechanisms, how loss of DAL-1 disturbs epithelial polarity with the outcome of EMT, are hindered by the enormous complexity of these processes. E-cadherin was observed to be upregulated after DAL-1 reexpression. Consistent with previous report, we confirmed that E-cadherin upregulation was sufficient to inhibit EMT in lung cancer cells [28]. We demonstrated that DAL-1 might increase the expression of E-cadherin via transcriptional activating the E-cadherin promoter. Our result of the dual-luciferase reporter assay and ChIP analysis identified that DAL-1 could bind E-cadherin promoter directly and increase expression of E-cadherin as a transcriptional factor. Recent study identified a putative NSL (nuclear localization signal) in exon 12 of DAL-1 [29]. Interestingly, a casein kinase II site, SAAE, is 26 amino acids upstream of the NLS in exon 12. It has been reported that proteins containing an NLS often have casein kinase II site 10–30 amino acids from the NLS [30]. The conformation of DAL-1 would be changed if the kinase site was phosphorylated, and the NLS would be exposed to be identified, leading DAL-1 into nuclear to act a role as transcriptional factor.

DAL-1 as an important component of membrane-associated cytoskeleton was originally detected in cell-cell junction part. DAL-1 contains some specific domains, including SABD and FERM domains [31,32] which lead DAL-1 function as a scaffold protein binding to the cell membrane and connecting to the cytoskeleton [27,33,34]. This kind of structure is essential for the maintainance of cell polarity and cell-cell adhesion [35,36]. Loss of DAL-1 may cause impairing of this structure and result in EMT development.

DAL-1 associated proteins were investigated by co-immunoprecipitation assay. E-cadherin, β-tubulin, P4HA1, 14-3-3ε and HSPA5 had been found in the DAL-1 binding complex. Previous research showed that DAL-1 interacted with 14-3-3ε and contributed to cell apoptosis [37,38]. So we performed endogenous co-immunoprecipitation experiment to conform the direct interaction between DAL-1 and P4HA1, E-cadherin or HSPA5. P4HA1 as a Prolyl hydroxylase family member could upregulate E-cadherin expression via induce HIF degradation [39,40]. The results showed that only HSPA5 was the combined protein to DAL-1. Molecular chaperone HSPA5 was a key survival factor in development and cancer [41]. HSPA5 may also be important for tumor metastasis because it is elevated in metastatic cancer cell lines, lymph node metastasis, and knockdown of HSPA5 inhibits tumor cell invasion in vitro and growth and metastasis in xenograft models [42,43]. The notable component of our work described here was that HSPA5 interacted with DAL-1 directly. HSPA5 knockdown could impact on EMT markers. Whether DAL-1 suppresses EMT via inhibiting HSPA5, further investigations will explore this mechanism.

Conclusions

In this study, we have demonstrated that the endogenous expression of DAL-1 was negatively correlated with the tumor pathological grading of clinical lung cancer samples. Further in vitro experiments have showed that DAL-1 reduced migration and invasion, transcriptional activated E-cadherin promoter. Moreover, HSPA5 as a DAL-1 co-precipitated protein contributed in EMT process. Based on our observations and results reported by other groups, we have proposed DAL-1 could attenuate EMT and be important for tumor metastasis in the early transformation process of lung cancer. The experimental data and conclusions in the present study furnish valuable information regarding the biological functions of DAL-1 and the possible mechanism of the migration and invasion of lung tumor. Thus, further studies will be focused on the molecular network involved in the DAL-1 regulation on EMT.

Notes

Abbreviations

DAL-1: 

Differentially expressed in adenocarcinoma of the lung-1

EMT: 

Epithelial-to mesenchymal transition

NSCLC: 

Non small cell carcinoma

HSPA5: 

Heat shock protein A5

Declarations

Acknowledgements

This work was supported by Doctoral Fund of Ministry of Education of China (NO. 20134423110001); Science and Technology Program of Guangzhou (NO. 2014Y2-00171); Guangzhou Municipal Education Department Innovation team grant (NO.13C06); Natural Science Foundation of Guangdong Province (No.S2012010010181)002E.

Authors’ Affiliations

(1)
Department of Pathology, School of Basic Medical Science, Guangzhou Medical University

References

  1. Subramaniam S, Thakur RK, Yadav VK, Nanda R, Chowdhury S, Agrawal A. Lung cancer biomarkers: State of the art. J Carcinog. 2013;12:3.PubMed CentralPubMedView ArticleGoogle Scholar
  2. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818–29.PubMedView ArticleGoogle Scholar
  3. Tran YK, Bogler O, Gorse KM, Wieland I, Green MR, Newsham IF. A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res. 1999;59(1):35–43.PubMedGoogle Scholar
  4. Steenbergen RD, Kramer D, Braakhuis BJ, Stern PL, Verheijen RH, Meijer CJ, et al. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst. 2004;96(4):294–305.PubMedView ArticleGoogle Scholar
  5. Lu B, Di W, Wang H, Ma H, Li J, Zhang Q. Tumor suppressor TSLC1 is implicated in cell proliferation, invasion and apoptosis in laryngeal squamous cell carcinoma by regulating Akt signaling pathway. Tumour Biol. 2012;33(6):2007–17.PubMedView ArticleGoogle Scholar
  6. Heller G, Geradts J, Ziegler B, Newsham I, Filipits M, Markis-Ritzinger EM, et al. Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat. 2007;103(3):283–91.PubMedView ArticleGoogle Scholar
  7. Ito T, Shimada Y, Hashimoto Y, Kaganoi J, Kan T, Watanabe G, et al. Involvement of TSLC1 in progression of esophageal squamous cell carcinoma. Cancer Res. 2003;63(19):6320–6.PubMedGoogle Scholar
  8. Kikuchi S, Yamada D, Fukami T, Masuda M, Sakurai-Yageta M, Williams YN, et al. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin Cancer Res. 2005;11(8):2954–61.PubMedView ArticleGoogle Scholar
  9. Goto A, Niki T, Chi-Pin L, Matsubara D, Murakami Y, Funata N, et al. Loss of TSLC1 expression in lung adenocarcinoma: relationships with histological subtypes, sex and prognostic significance. Cancer Sci. 2005;96(8):480–6.PubMedView ArticleGoogle Scholar
  10. Kuns R, Kissil JL, Newsham IF, Jacks T, Gutmann DH, Sherman LS. Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation. Oncogene. 2005;24(43):6502–15.PubMedGoogle Scholar
  11. Busam RD, Thorsell AG, Flores A, Hammarstrom M, Persson C, Obrink B, et al. Structural basis of tumor suppressor in lung cancer 1 (TSLC1) binding to differentially expressed in adenocarcinoma of the lung (DAL-1/4.1B). J Biol Chem. 2011;286(6):4511–6.PubMed CentralPubMedView ArticleGoogle Scholar
  12. Garufi A, D’Orazi G. High glucose dephosphorylates serine 46 and inhibits p53 apoptotic activity. J Exp Clin Cancer Res. 2014;33:79.PubMed CentralPubMedView ArticleGoogle Scholar
  13. Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 2011;21(1):35–43.PubMed CentralPubMedView ArticleGoogle Scholar
  14. Soda K. The mechanisms by which polyamines accelerate tumor spread. J Exp Clin Cancer Res. 2011;30:95.PubMed CentralPubMedView ArticleGoogle Scholar
  15. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591–601.PubMedView ArticleGoogle Scholar
  16. Bonomi M, Pilotto S, Milella M, Massari F, Cingarlini S, Brunelli M, et al. Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. J Exp Clin Cancer Res. 2011;30:115.PubMed CentralPubMedView ArticleGoogle Scholar
  17. Spano D, Heck C, De Antonellis P, Christofori G, Zollo M. Molecular networks that regulate cancer metastasis. Semin Cancer Biol. 2012;22(3):234–49.PubMedView ArticleGoogle Scholar
  18. Jan YH, Tsai HY, Yang CJ, Huang MS, Yang YF, Lai TC, et al. Adenylate kinase-4 is a marker of poor clinical outcomes that promotes metastasis of lung cancer by downregulating the transcription factor ATF3. Cancer Res. 2012;72(19):5119–29.PubMedView ArticleGoogle Scholar
  19. Kaufhold S, Bonavida B. Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. J Exp Clin Cancer Res. 2014;33:62.PubMed CentralPubMedView ArticleGoogle Scholar
  20. Franco-Chuaire ML, Magda Carolina SC, Chuaire-Noack L. Epithelial-mesenchymal transition (EMT): principles and clinical impact in cancer therapy. Invest Clin. 2013;54(2):186–205.PubMedGoogle Scholar
  21. Richardson F, Young GD, Sennello R, Wolf J, Argast GM, Mercado P, et al. The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy. Anticancer Res. 2012;32(2):537–52.PubMedGoogle Scholar
  22. Bastid J. EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations. Cancer Metastasis Rev. 2012;31(1–2):277–83.PubMedView ArticleGoogle Scholar
  23. Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, Campan M, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 2012;22(7):1197–211.PubMed CentralPubMedView ArticleGoogle Scholar
  24. Takahashi Y, Iwai M, Kawai T, Arakawa A, Ito T, Sakurai-Yageta M, et al. Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer. Breast Cancer. 2012;19(3):242–52.PubMedView ArticleGoogle Scholar
  25. Maher ER. Genomics and epigenomics of renal cell carcinoma. Semin Cancer Biol. 2013;23(1):10–7.PubMedView ArticleGoogle Scholar
  26. Nunomura W, Denker SP, Barber DL, Takakuwa Y, Gascard P. Characterization of cytoskeletal protein 4.1R interaction with NHE1 (Na(+)/H(+) exchanger isoform 1). Biochem J. 2012;446(3):427–35.PubMedView ArticleGoogle Scholar
  27. Ohno N, Terada N, Komada M, Saitoh S, Costantini F, Pace V, et al. Dispensable role of protein 4.1B/DAL-1 in rodent adrenal medulla regarding generation of pheochromocytoma and plasmalemmal localization of TSLC1. Biochim Biophys Acta. 2009;1793(3):506–15.PubMedView ArticleGoogle Scholar
  28. Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer. 2010;9:179.PubMed CentralPubMedView ArticleGoogle Scholar
  29. Kittiniyom K, Mastronardi M, Roemer M, Wells WA, Greenberg ER, Titus-Ernstoff L, et al. Allele-specific loss of heterozygosity at the DAL-1/4.1B (EPB41L3) tumor-suppressor gene locus in the absence of mutation. Genes Chromosomes Cancer. 2004;40(3):190–203.PubMedView ArticleGoogle Scholar
  30. Gascard P, Parra MK, Zhao Z, Calinisan VR, Nunomura W, Rivkees SA, et al. Putative tumor suppressor protein 4.1B is differentially expressed in kidney and brain via alternative promoters and 5′ alternative splicing. Biochim Biophys Acta. 2004;1680(2):71–82.PubMedView ArticleGoogle Scholar
  31. Kang Q, Wang T, Zhang H, Mohandas N, An X. A Golgi-associated protein 4.1B variant is required for assimilation of proteins in the membrane. J Cell Sci. 2009;122(Pt 8):1091–9.PubMed CentralPubMedView ArticleGoogle Scholar
  32. Wang H, Liu C, Debnath G, Baines AJ, Conboy JG, Mohandas N, et al. Comprehensive characterization of expression patterns of protein 4.1 family members in mouse adrenal gland: implications for functions. Histochem Cell Biol. 2010;134(4):411–20.PubMedView ArticleGoogle Scholar
  33. Horresh I, Bar V, Kissil JL, Peles E. Organization of myelinated axons by Caspr and Caspr2 requires the cytoskeletal adapter protein 4.1B. J Neurosci. 2010;30(7):2480–9.PubMed CentralPubMedView ArticleGoogle Scholar
  34. Buttermore ED, Dupree JL, Cheng J, An X, Tessarollo L, Bhat MA. The cytoskeletal adaptor protein band 4.1B is required for the maintenance of paranodal axoglial septate junctions in myelinated axons. J Neurosci. 2011;31(22):8013–24.PubMed CentralPubMedView ArticleGoogle Scholar
  35. Einheber S, Meng X, Rubin M, Lam I, Mohandas N, An X, et al. The 4.1B cytoskeletal protein regulates the domain organization and sheath thickness of myelinated axons. Glia. 2013;61(2):240–53.PubMed CentralPubMedView ArticleGoogle Scholar
  36. Cifuentes-Diaz C, Chareyre F, Garcia M, Devaux J, Carnaud M, Levasseur G, et al. Protein 4.1B contributes to the organization of peripheral myelinated axons. PLoS One. 2011;6(9):e25043.PubMed CentralPubMedView ArticleGoogle Scholar
  37. Ko BS, Chang TC, Hsu C, Chen YC, Shen TL, Chen SC, et al. Overexpression of 14-3-3epsilon predicts tumour metastasis and poor survival in hepatocellular carcinoma. Histopathology. 2011;58(5):705–11.PubMedView ArticleGoogle Scholar
  38. Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, et al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J. 2010;430(3):405–13.PubMed CentralPubMedView ArticleGoogle Scholar
  39. Cheng JC, Klausen C, Leung PC. Hypoxia-inducible factor 1 alpha mediates epidermal growth factor-induced down-regulation of E-cadherin expression and cell invasion in human ovarian cancer cells. Cancer Lett. 2013;329(2):197–206.PubMedView ArticleGoogle Scholar
  40. Kim HJ, Park JW, Cho YS, Cho CH, Kim JS, Shin HW, et al. Pathogenic role of HIF-1alpha in prostate hyperplasia in the presence of chronic inflammation. Biochim Biophys Acta. 2013;1832(1):183–94.PubMedView ArticleGoogle Scholar
  41. Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res. 2007;67(8):3496–9.PubMedView ArticleGoogle Scholar
  42. Zhang J, Jiang Y, Jia Z, Li Q, Gong W, Wang L, et al. Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis. 2006;23(7–8):401–10.PubMedGoogle Scholar
  43. Wu HM, Jiang ZF, Fan XY, Wang T, Ke X, Yan XB, et al. Reversed expression of GRIM-1 and GRP78 in human non-small cell lung cancer. Hum Pathol. 2014;45(9):1936–43.PubMedView ArticleGoogle Scholar

Copyright

© Chen et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement